

**EXAMINER**

Atif Shamim

**DATE CONSIDERED**

12/3/61

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. P20670	Serial No. 09/763,617
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use several sheets if necessary)		Applicant K. WANNER et al.	
		Filing Date September 3, 1999	Group 1626

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

O I P E G S JUN 21 2001 P A T E N T & T R A D E M A R K Q U E R E L L E G S	<p>1 PAVIA, Michael R., et al.: Structure-Activity Studies on Benzhydrol-Containing Nipecotic Acid and Guvacine Derivatives as Potent, Orally-Active Inhibitors of GABA Uptake. In: J. Med. Chem. 1992, 35, pp 4238-4248;</p>
	<p>2 ANDERSEN, Knud Erik, et al.: The Synthesis of Novel GABA Uptake Inhibitors. 1. Elucidation of the Structure-Activity Studies Leading to Choice of (R)-1-[4,4-Bis(3-methyl-2-thienyl)-3-butenyl]-3-piperidinocarboxylic Acid (Tiagabine) as an Anticonvulsant Drug Candidate. In: J. Med. Chem. 1993 pp. 1716-1725.</p>
	<p>3 Suzak, Peter D.: Lipophilic GABA uptake inhibitors: Biochemistry, pharmacology and therapeutic potential. In: Drugs of the Future 1993, 18(12), pp. 1129-1136;</p>
	<p>4 Murali Dhar, T.G., et al: Design, Synthesis and Evaluation of Substituted Triarylnipecotic Acid Derivatives as GABA Uptake Inhibitors: Identification of a Ligand with Moderate Affinity and Selectivity for the Cloned Human GABA Transporter GAT-3. In: J. Med. Chem. 1994, 37, pp. 2334-2342.</p>
	<p>5 Thomsen, C., et al.: 1-(3-(9H-Carbazol-9-yl)-1-propyl)-4-(2-methoxyphenyl)-4-piperidinol, a novel subtype selective inhibitor of the mouse type II GABA-transporter. In: British Journal of Pharmacology (1997) 120, 983-985.</p>

**EXAMINER**

Mr. hameem

**DATE CONSIDERED**

123101

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.